View Older Stories View More Recent Stories

Aug 19, 2022 07:32AM Intercept Pharma (ICPT) Announces Repurchase of Convertible Notes
Aug 19, 2022 07:30AM Intercept Pharmaceuticals Announces Repurchase of Convertible Notes
Aug 18, 2022 08:00AM Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022
Aug 3, 2022 07:00AM Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 27, 2022 08:00AM Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
Jul 7, 2022 07:30AM Intercept Pharma (ICPT) Reports Positive Data in Fibrosis due to NASH from New Analysis of its Phase 3 REGENERATE Study of OCA
Jul 7, 2022 07:30AM Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
Jul 1, 2022 04:01PM Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.
Jun 21, 2022 07:32AM Intercept Pharma (ICPT) Announces PBC Data Presentations at The International Liver Congress 2022
Jun 21, 2022 07:30AM Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022
Jun 6, 2022 06:31AM Intercept Pharma (ICPT) Provides Update on NASH Regulatory Timeline, Pre-submission Meeting Moved to July
Jun 6, 2022 06:30AM Intercept Provides Update on NASH Regulatory Timeline
Jun 3, 2022 07:32AM Intercept Pharma (ICPT) Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC
Jun 3, 2022 07:30AM Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC
May 11, 2022 08:00AM Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis
May 6, 2022 07:00AM Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 07:18AM Intercept Pharma (ICPT) Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450M
May 5, 2022 07:17AM Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments
May 2, 2022 08:00AM Intercept to Announce First Quarter 2022 Financial Results on May 6, 2022
Mar 2, 2022 07:00AM Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update
Feb 23, 2022 08:49AM Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022
Dec 20, 2021 08:01AM Intercept Pharma (ICPT) Announces Phase 3 REVERSE Trial Topline Data Will be Delayed till Q1 2022
Dec 20, 2021 08:00AM Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH
Dec 9, 2021 07:02AM Intercept Pharma (ICPT) Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH
Dec 9, 2021 07:00AM Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH
Nov 15, 2021 08:04AM Intercept Pharma (ICPT) Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC
Nov 15, 2021 08:00AM Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC
Nov 11, 2021 08:00AM Intercept to Present at Upcoming Investor Conferences
Nov 3, 2021 07:00AM Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 2, 2021 08:11AM Intercept Pharma (ICPT) Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting
Nov 2, 2021 08:00AM Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting
Oct 27, 2021 08:00AM Intercept to Announce Third Quarter 2021 Financial Results on November 3, 2021
Sep 21, 2021 08:00AM Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference
Jul 29, 2021 07:00AM Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Jul 19, 2021 07:00AM Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021
Jun 21, 2021 08:00AM Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021
Jun 15, 2021 08:00AM Intercept to Present at the Raymond James 2021 Human Health Innovation Conference
Jun 9, 2021 08:05AM Intercept Pharma (ICPT) Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer
Jun 9, 2021 08:00AM Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer
Jun 7, 2021 08:00AM Intercept Appoints Andrew Saik as Chief Financial Officer
May 27, 2021 08:00AM Intercept to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021 04:31PM Intercept Pharma (ICPT) Announces Updated Ocaliva U.S. Prescribing Information
May 26, 2021 04:30PM Intercept Announces Updated Ocaliva® (obeticholic acid) U.S. Prescribing Information
May 12, 2021 08:00AM Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference
May 6, 2021 07:00AM Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
Apr 26, 2021 08:00AM Intercept to Announce First Quarter 2021 Financial Results on May 6, 2021
Mar 10, 2021 08:05AM Intercept Pharma (ICPT) Announces Departure of Chief Financial Officer
Mar 10, 2021 08:00AM Intercept Announces Departure of Chief Financial Officer
Feb 25, 2021 07:00AM Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update
Feb 23, 2021 08:27AM Intercept Pharma (ICPT) Announces Dagmar Rosa-Bjorkeson to Board
View More Recent Stories View Older Stories